Tolerability and adherence issues in antidepressant therapy

被引:168
作者
Masand, PS [1 ]
机构
[1] Duke Univ, Med Ctr, Program Continuing Med Educ, Durham, NC 27710 USA
关键词
depression; antidepressant; adherence; discontinuation;
D O I
10.1016/S0149-2918(03)80220-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Despite the availability of effective antidepressants, recurrence and relapse rates for depression are high (up to 80%), treatment failures are common (40% to 60%), and as many as 20% of patients remain inadequately treated. Depression treatment guidelines are often not followed, and rates of nonadherence to treatment are high, with 28% of patients discontinuing antidepressant treatment within the first month and 44% discontinuing within 3 months of initiating therapy. Objective: The aim of this article was to summarize research on antidepressant therapy nonadherence and examine the limitations of strategies used to minimize adverse events (AEs) and improve treatment duration. Methods: A thorough search of the published literature from 1990 to the present was performed on MEDLINE and other search engines. The following search terms were used: tolerability, antidepressants, patient compliance, adherence, therapy, SSRIs, tricyclics, and other related terms focusing on specific agents. Results: Physician-specific issues represent some of the most important obstacles to adequate antidepressant therapy Inadequate patient education, prescription of inappropriate medications or inadequate dosages, and lack of follow-up care are all issues the physician can control to improve patient adherence. Patient-specific issues include poor motivation (due to symptoms of depression) to continue therapy, failure to perceive a benefit, and concerns about cost of therapy Medication-specific issues such as treatment-related AEs, delayed onset of action, complicated dosing or titration schedule, and subtherapeutic dosing also contribute to treatment discontinuation. Therapy with greater than or equal to1 antidepressant and/or atypical antipsychotic may improve symptom control, but little evidence exists regarding efficacy and safety Dosage reduction has been attempted to reduce events that may lead to patient discontinuation, but this may increase the risk of recurrent depressive episodes. Conclusions: To maximize patient adherence to antidepressant therapy, it is necessary to combine adequate treatment duration, realistic patient expectations, and the right dose of an agent capable of treating the full range of symptoms while controlling for AEs. Copyright (C) 2003 Excerpta Medica, Inc.
引用
收藏
页码:2289 / 2304
页数:16
相关论文
共 59 条
  • [1] Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability
    Anderson, IM
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2000, 58 (01) : 19 - 36
  • [2] [Anonymous], 2000, Am J Psychiatry, V157, P1
  • [3] [Anonymous], 2001, Goodman Gilman's The Pharmacological Basis of Therapeutics
  • [4] [Anonymous], 2002, SERZ PACK INS
  • [5] Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis
    Beasley, CM
    Koke, SC
    Nilsson, ME
    Gonzales, JS
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (11) : 1319 - +
  • [6] Discontinuing or switching selective serotonin-reuptake inhibitors
    Bull, SA
    Hunkeler, EM
    Lee, JY
    Rowland, CR
    Williamson, TE
    Schwab, JR
    Hurt, SW
    [J]. ANNALS OF PHARMACOTHERAPY, 2002, 36 (04) : 578 - 584
  • [7] Discontinuation of use and switching of antidepressants - Influence of patient-physician communication
    Bull, SA
    Hu, XH
    Hunkeler, EM
    Lee, JY
    Ming, EE
    Markson, LE
    Fireman, B
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (11): : 1403 - 1409
  • [8] BURKE WJ, ARE 2 MONOAMINES BET
  • [9] Achieving remission with venlafaxine and fluoxetine in major depression: Its relationship to anxiety symptoms
    Davidson, JRT
    Meoni, P
    Haudiquet, V
    Cantillon, M
    Hackett, D
    [J]. DEPRESSION AND ANXIETY, 2002, 16 (01) : 4 - 13
  • [10] de Klerk E, 2001, J CLIN PSYCHIAT, V62, P43